2024Antimicrobial agents and chemotherapy68 (3) : e0121023
Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
Haid S, Matthaei A, Winkler M, Sake S, Gunesch A, Milke V, Köhler N, Rückert J, Vieyres G, Kühl D, Nguyen T, Göhl M, Lasswitz L, Zapatero-Belinchón F, Brogden G, Gerold G, Wiegmann B, Bilitewski U, Brown R, Brönstrup M, Schulz T, Pietschmann T
2024Nature communications15 (1) : 1173
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
Sake S, Zhang X, Rajak M, Urbanek-Quaing M, Carpentier A, Gunesch A, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee A, Johnson K, Morwood K, Rox K, Elgaher W, Huang J, Wetzke M, Hansen G, Fischer N, Eléouët J, Rameix-Welti M, Hirsch A, Herold E, Empting M, Lauber C, Schulz T, Krey T, Haid S, Pietschmann T
2023The Journal of hospital infection141 : 25-32
Virucidal activity of oral, hand, and surface disinfectants against respiratory syncytial virus
Meister T, Friesland M, Frericks N, Wetzke M, Haid S, Steinmann J, Todt D, Pietschmann T, Steinmann E